友芝友生物－Ｂ (2496.HK)

7.450 0.000 (0.00%) 收市：03:46PM HKT

友芝友生物－Ｂ

Building C2-1, Optics Valley Biocity
No. 666 Gaoxin Avenue East Lake New Technology Development Zone
Wuhan 430075
China
86 27 8266 8988
https://www.yzybio.com

版塊: Healthcare
行業: Biotechnology
全職員工: 123

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. Pengfei Zhou / Ph.D., M.D.	Chairman of the Board & CEO	2.66M	無	1967
Dr. Jizu Yi	Senior Vice President of Quality	無	無	1963
Mr. Jing Zhang	Senior Director of the R&D Center and Supervisor	無	無	1983
Mr. Jianhua Zheng	Senior Manager of Strategic Development Department & Joint Company Secretary	無	無	無
Ms. Tin Yun Lai	Joint Company Secretary	無	無	1989

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 HKD。

描述

Wuhan YZY Biopharma Co., Ltd., a biotechnology company, develops bispecific antibody-based therapies for the treatment of cancer, cancer-related complications, and age-related eye diseases. It develops various product candidates for the treatment of malignant ascites, malignant pleural effusion, solid tumors, pancreatic cancer, hepatocellular carcinoma and other advanced solid tumors, small cell lung cancer, relapsed/refractory multiple myeloma, and HER2-positive solid tumors; and covid 19 indication, as well as wAMD, DME, and other ocular neovascularization-related diseases. The company was founded in 2010 and is based in Wuhan, China.

公司管治

截至 無 止，友芝友生物－Ｂ 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。